# 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

> **NCT04832438** · PHASE2 · WITHDRAWN · sponsor: **Actuate Therapeutics Inc.**

## Conditions studied

- Salivary Gland Carcinoma
- Adenoid Cystic Carcinoma
- Salivary Gland Cancer
- Salivary Gland Neoplasms

## Interventions

- **DRUG:** 9-ING-41
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04832438
- **Lead sponsor:** Actuate Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2030-12-18
- **Primary completion:** 2033-06-18
- **Final completion:** 2034-06-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Replaced by NCT05010629
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04832438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04832438, "9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04832438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*